vimarsana.com
Home
Live Updates
Long-Term Freedom From NMOSD Relapse With Satralizumab : vimarsana.com
Long-Term Freedom From NMOSD Relapse With Satralizumab : vimarsana.com
Long-Term Freedom From NMOSD Relapse With Satralizumab
The use of the monoclonal antibody satralizumab for the long-term treatment of neuromyelitis optica spectrum disorder provides sustained freedom from relapse with no new safety concerns over 5 years.
Related Keywords
Denver ,
Colorado ,
United States ,
Tennessee ,
Canada ,
Vancouver ,
British Columbia ,
United Kingdom ,
British ,
Shailee Shah ,
Anthony Traboulsee ,
Consortium Of Multiple Sclerosis Centers ,
Neuroimmunology Division At Vanderbilt University Medical Center ,
University Of British Columbia ,
Drug Administration ,
Multiple Sclerosis Centers ,
Medscape Medical ,
Expanded Disability Status Scale ,
Good First Line ,
Medscape Medical News ,
Neuroimmunology Division ,
Vanderbilt University Medical Center ,
Multiple Sclerosis Ms ,
Ultiple Sclerosis ,
S ,
Biologic Therapy ,
Disability ,
Monoclonal Antibody ,
Etuximab ,
Ituximab ,
Neuromyelitis Optica Nmo ,
Devics Disease ,
Evics Syndrome ,
Igg ,
Patient Safety ,
Adverse Effects ,
Ide Effects ,
Boards ,
Smle ,
,
Csf ,
Chronic Disease ,
Hronic Illness ,
Clinical Research ,
Linical Trials ,
Linical Studies ,
Elderly Concerns Of Older Adults ,
Geriatrics Elder Care ,
Immunizat ,